Analysis for CMCSA

$21.77 +0.72 (+3.42%)

📈 Growth — 8/30
💰 Profitability — 16/20
🏦 Financial Health — 14/20
💵 Valuation — 12/20
⚠️ Risk — 6/10

Overall Score: 54/100

Summary:

📈 Growth & Financial Trajectory

Over the eight quarters, revenues hover in the low-30s billions with modest drift; start Q1 2024 revenues were around $30.06B and end Q2 2026 around $29.94B, a slight (-0.4%) decline. Net income attributable to parent moved from about $3.86B in early 2024 to $3.53B by mid-2026, with volatility driven by non-operating items. Operating income stayed in the $5–6B band, signaling durable earnings power despite flat revenue.

💰 Margins & Cash Flow

Operating margins run roughly in the high teens (approximately 18–21%), with Q4 2024 and several quarters near the mid-20s on stronger quarterly performance. Net cash flow from operating activities generally ranges $7–9B per quarter; investing/financing cash flows are often negative, producing uneven free cash flow. Q2 2026 shows a small negative overall cash flow, while other quarters show positive cash generation.

🛡️ Balance Sheet & Liquidity

Total assets run around $260–273B with equity near $86–97B and liabilities around $171–180B. Current assets and current liabilities place near-term liquidity around parity-to-light liquidity risk, supported by a strong equity base.